Heparin Versus Saline Locking of Peripheral Venous Catheters (HESAL)
Heparin Versus Saline Locking of Peripheral Venous Catheters: a Multicenter Retrospective Cohort Study
The goal of this observational study is to learn whether locking peripheral venous catheters with heparin keeps them open (patent) better than locking them with saline, in adults admitted to hospital who have a peripheral venous catheter for intermittent treatment. The main questions it aims to answer are:
- Is the percentage of blocked peripheral venous catheters higher in patients whose catheters are locked with saline than in those whose catheters are locked with heparin?
- Do the rates of other catheter-related complications (phlebitis, catheter-related bloodstream infection, extravasation, and leakage at the insertion site) differ between the two groups?
- Which clinical and drug-related factors are associated with catheter blockage?
Researchers will compare patients admitted to a hospital that routinely locks catheters with saline with patients admitted to a hospital that routinely locks catheters with heparin.
調査の概要
詳細な説明
Maintaining the patency of peripheral venous catheters (PVCs) used intermittently is a relevant and unresolved clinical question. Reference care bundles such as Bacteremia Zero and Phlebitis Zero do not explicitly address whether catheters should be locked with saline or heparin, and the evidence comparing both options, especially taking into account the interval between infusions, is limited.
The two hospitals of the Consorci Sanitari de l'Alt Penedès i Garraf offer a natural experiment: Hospital Residència Sant Camil systematically locks PVCs with sodium heparin 20 IU/mL , while Hospital Comarcal de l'Alt Penedès locks them with sterile 0.9% saline. Allocation to each cohort is determined solely by the hospital of admission. Data for the year before the start of the study will be extracted retrospectively from the electronic medical record, where nurses record the status of the catheter and the reason for removal or replacement on each shift.
The primary analysis will compare, with a superiority approach, the percentage of blocked catheters between cohorts, considering only the first catheter inserted in each patient. Logistic regression will adjust for confounders that are unbalanced between cohorts or clinically relevant (age, sex, type and schedule of intravenous medication, anticoagulation, and coagulation disorders). Sensitivity analyses will include all catheters per patient (mixed models or generalized estimating equations) and will exclude patients at particularly high risk of blockage. Assuming an absolute difference of 3% between cohorts, alpha 5%, power 80%, and 5% losses, 1,725 patients per cohort (3,450 in total) are needed. Data analysts will be blinded to the cohort during the primary analysis.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Noemí Casaponsa
- 電話番号:43197 0034938960025
- メール:recerca@csapg.cat
研究場所
-
-
Barcelona
-
Sant Pere de Ribes、Barcelona、スペイン、08810
- Hospital Residència Sant Camil
-
コンタクト:
- Noemí Casaponsa
- 電話番号:43197 0034938960025
- メール:recerca@csapg.cat
-
主任研究者:
- Esther Moreno Rubio
-
Vilafranca del Penedès、Barcelona、スペイン、08720
- Hospital Comarcal de l'Alt Penedès
-
コンタクト:
- Noemí Casaponsa
- 電話番号:43197 0034938960025
- メール:recerca@csapg.cat
-
主任研究者:
- Esther Moreno Rubio
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
All adults admitted to Hospital Residència Sant Camil or Hospital Comarcal de l'Alt Penedès (both hospital belonging to CSAPG) during the study period who had at least one peripheral venous catheter inserted for intermittent treatment.
説明
Inclusion Criteria:
- Admitted to Hospital Residència Sant Camil (CSAPG) or Hospital Comarcal de l'Alt Penedès (CSAPG) during the study period
- At least one peripheral venous catheter for intermittent treatment, not inserted in a medical emergency
- Aged 18 years or older
Exclusion Criteria:
- Known allergy to heparin
- Treatment with systemic unfractionated sodium heparin
- Dialysis
- Venous catheter used only for diagnostic tests
- Venous catheter used only for transfusion of blood products
- Participation in another clinical study with drugs or procedures that may affect catheter patency
- Severe heparin-induced thrombocytopenia in recent months
- Uncontrolled active bleeding during admission
- Cerebral aneurysm or dissecting aortic aneurysm, except in association with corrective surgery
- Confirmed or suspected cerebrovascular hemorrhage
- Severe uncontrolled hypertension
- Severe coagulation disorders: platelets below 30,000/µL, prothrombin time ratio above 1.7, or activated partial thromboplastin time ratio above 1.7
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:RETROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Cohort A: saline locking
|
|
Cohort B: heparin locking
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of blocked peripheral venous catheters
時間枠:Hospital discharge, up to 12 weeks
|
Percentage of patients whose first peripheral venous catheter was removed or replaced because of blockage (occlusion). |
Hospital discharge, up to 12 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CSAPG-98
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).
IPD 共有時間枠
After publication of main results of the study.
IPD 共有アクセス基準
IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。